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Abstract: The interaction of a small library of cyclic RGD (Arg-Gly-Asp) peptidomimetics with αVβ6
integrin has been investigated by means of competitive solid phase binding assays to the isolated
receptor and docking calculations in the crystal structure of the αVβ6 binding site. To this aim,
a rigid receptor-flexible ligand docking protocol has been set up and then applied to predict the
binding mode of the cyclic RGD peptidomimetics to αVβ6 integrin. Although the RGD interaction
with αVβ6 recapitulates the RGD binding mode observed in αVβ3, differences between the integrin
binding pockets can strongly affect the ligand binding ability. In general, the peptidomimetics
exhibited IC50 values for integrin αVβ6 (i.e., the concentration of compound required for 50%
inhibition of biotinylated fibronectin binding to isolated αVβ6 integrin) in the nanomolar range
(77–345 nM), about 10–100 times higher than those for the related αVβ3 receptor, with a single notable
ligand displaying a low nanomolar IC50 value (2.3 nM). Insights from the properties of the binding
pocket combined with the analysis of the docking poses provided a rationale for ligand recognition
and selectivity.
Keywords: RGD peptidomimetics; integrins; molecular docking; binding assays
1. Introduction
Integrins are αβ-heterodimeric transmembrane proteins that are involved in cell adhesion and
signaling [1,2]. Because of their central role in a variety of physiological cell functions, as well as
in the pathobiology of many diseases, integrins continue to attract interest for the development of
therapeutic agents [3–7]. For instance, in cancer, pharmacological research is focused on a group of
integrins that play key roles in tumor angiogenesis, progression, and metastasis, and share the property
to recognize ligands containing the RGD (Arg-Gly-Asp) sequence, with a specificity determined by
the features of the binding pocket and the context of the ligand RGD motif (i.e., flanking residues,
conformation) [8–10].
Driven by the functional roles and the upregulated expression on various tumor cells of several
subtypes from the RGD-binding subfamily, such as α5β1 along with αVβ3 and other αV integrins,
extensive chemical research has been carried out to develop RGD-based peptidic and peptidomimetic
Cancers 2017, 9, 128; doi:10.3390/cancers9100128 www.mdpi.com/journal/cancers
Cancers 2017, 9, 128 2 of 13
integrin ligands as inhibitors of integrin functions and as targeting devices for the selective delivery of
drugs or imaging probes to tumors [9–16].
Among them, the best known RGD peptide is the cyclic pentapeptide cyclo[RGDf(N-Me)V]
1a (Cilengitide, Figure 1a) [17], the first integrin antagonist to be tested in clinical trials [18], that is
currently undergoing phase II studies for the treatment of several cancer types after its failure in a phase
III trial for the treatment of patients with newly diagnosed glioblastoma [19,20]. Other well-known
RGD peptides are cyclo[RGDfV] 1b, the parent peptide of Cilengitide, and cyclo[RGDfK] 1c,
that has been extensively used as targeting motif for targeted cancer diagnosis and therapy studies
(Figure 1a) [10,13–16,21].
With the aim of developing new small molecule integrin antagonists with improved properties,
we have recently synthesized a small library of cyclic RGD peptidomimetic integrin ligands,
containing bifunctional diketopiperazine (DKP) scaffolds that differ in the configuration at the two
DKP stereocenters and in the substitution at the DKP nitrogen atoms, and that can be viewed as
conformationally constrained dipeptide mimics formed by two β-amino acids (Figure 1b) [22–24].
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Figure 1. (a) Cyclic RGD (Arg-Gly-Asp) pentapeptides 1a–c; (b) Cyclic RGD peptidomimetics 2–7
containing DKP scaffolds.
In particular, the cyclic RGD peptidomimetics 2–7 derived from trans-DKP scaffolds (DKP2-DKP7)
were shown to bind αVβ3, αVβ5, and α5β1 integrins with a preferential affinity towards αVβ3,
inhibiting the binding of biotinylated vitronectin to the purified αVβ3 integrin at low- or sub-nanomolar
IC50 values [24,25]. The interaction of the cyclic DKP-RGD peptidomimetics with αVβ3 and α5β1
integrins has been investigated by means of integrated spectroscopic and computational studies,
gaining insights into the molecular basis of their activity [24–26]. In particular, the preferred ligand
conformations, displaying an extended arrangement of the RGD motif with a distance of about 9 Å
between the Cβ atoms of Asp and Arg, are highly preorganized for the interaction with integrins αVβ3
and α5β1, as demonstrated by the docking studies in the crystal structures and NMR experiments
with αVβ3-rich bladder cancer cells and α5β1-rich breast cancer cells [24–26].
Recently, ligand 3 (Figure 1b) was reported to display inhibitory effects on the FAK/Akt
integrin-activated transduction signaling pathway and on integrin-mediated cell infiltration processes
in human glioblastoma cells, thus qualifying as a true integrin antagonist [27]. It was also
shown to significantly inhibit the cell adhesion of different cancer cells, and angiogenesis induced
by pro-angiogenic growth factors in human endothelial cells [28]. Moreover, after suitable
functionalization, it was exploited as a targeting agent for the preparation of conjugates designed to
release cytotoxic drugs selectively within cancer cells expressing αVβ3 integrin [29–31].
In this context, information on the ability of small RGD molecules to interact with closely related
integrin subtypes involved in cancer, is crucial to fully understand the biological activity profiles and
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to develop suitable integrin ligands for the modulation of integrin functions or the targeted delivery of
chemotherapy [9,10,13–16,21].
Prompted by its pathological relevance in cancer and by the availability of X-ray structural
information [32], we became interested in the integrin αVβ6, one of five αV integrins and the unique
β6 integrin from the RGD-binding subfamily. αVβ6 is expressed on epithelial cells, especially during
development, after injury or inflammation, or on many carcinomas. The ligand binding site of αVβ6
is in the N-terminal head region formed by the interaction of the αV β-propeller domain with the β6
βI domain. αVβ6 preferentially binds to the latency-associated peptide (LAP) of the transforming
growth factor-β (TGF-β), but can also recognize the matrix proteins fibronectin and tenascin. In this
regard, αVβ6 interacts with the LAP/TGF-β complex by binding with the RGD motif present in the
LAP peptide, thus breaking the latency complex and releasing the active form of TGF-β which, in turn,
binds to and activates its receptors on the cell surface [32,33]. In particular, similarly to integrin αVβ8,
αVβ6 is specialized to activate TGF-β1 and TGF-β3 from large latent complexes. Therefore, high αVβ6
expression in carcinomas may contribute to progression through its effects on TGF-β activity.
In the framework of a study investigating the determinants of αVβ6 high specificity for the RGD
motif present in the prodomain of TGF-β1 and TGF-β3, the crystal structures of the αVβ6 headpiece
with or without a pro-TGF-β3 undecapeptide have been recently solved [32]. The ligand-bound
structure revealed that αVβ6 recognizes not only RGD but also the adjacent C-terminal LGRLK motif
that folds into an amphipathic α-helix fitting into a hydrophobic pocket in the β6 subunit.
Herein, we report on the interaction of our cyclic DKP-RGD peptidomimetics with αVβ6 integrin
by means of competitive solid phase binding assays to the isolated receptor and docking calculations in
the crystal structure of the αVβ6 binding site. Starting from the structure of ligand-bound αVβ6, a rigid
receptor-flexible ligand docking protocol has been set up and then applied to predict the binding mode
of the cyclic RGD peptidomimetics to αVβ6 integrin. The analysis of the properties of the receptor
pocket, combined with the examination of the docking poses allowed to rationalize the experimental
binding affinities for the αVβ6 integrin, which turned out to be about 10–100 times lower than those for
the related αVβ3 receptor. On the basis of docking calculations, the best cyclic RGD peptidomimetic
was also identified, displaying a low nanomolar IC50 value.
2. Results
2.1. Integrin Receptor Competitive Binding Assays
The cyclic peptidic (1a–c) and peptidomimetic (2–7) RGD ligands were examined in vitro for
their ability to compete with biotinylated fibronectin for binding to the isolated αVβ6 integrin
(Table 1). The assay was performed according to previously reported procedures [24,25] with slight
modifications. In particular, a concentration of 1 µg/mL of integrin receptor was required for obtaining
an efficient coating of the plates and a good reproducibility of the data [21,34]. Various concentrations
(10−11–10−4 M) of the RGD ligands in the presence of biotinylated fibronectin (1 µg/mL) were then
added to the plates and finally bound fibronectin was revealed by using a streptavidin-biotinylated
peroxidase complex (see Section 4 for a detailed description).
To validate the binding assay protocol, the well-known cyclopeptidic integrin ligands 1a–c were
first assayed. Both compounds 1b (c[RGDfV]) and 1c (c[RGDfK]) showed binding affinities for integrin
αVβ6 (expressed as the ligand concentration required for 50% inhibition of endogenous ligand binding)
comparable with data recently reported in literature [21] (Table 1). A nanomolar IC50 value similar
to that of the other cyclopeptides was observed also for 1a (c[RGDf(N-Me)V], IC50 = 82.8 ± 4.9 nM),
in contrast with the micromolar value recently reported [21]. It must be noted that the two IC50 values
are obtained by competitive solid phase binding assays by using two different procedures and two
different αVβ6 natural ligands: immobilized integrin and soluble fibronectin in the present assay,
immobilized latency associated peptide (LAP), and soluble integrin in the other [21]. Noteworthy,
the present result is compatible with the outcomes of docking calculations (vide infra).
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Table 1. Inhibition of biotinylated fibronectin binding to αVβ6 integrin compared with inhibition of
biotinylated vitronectin binding to αVβ3.
Compound αVβ6 IC50 [nM] 1 αVβ3 IC50 [nM] 2 IC50 (αVβ6)/IC50 (αVβ3)
1a
c[RGDf(N-Me)V] 82.8 ± 4.9 0.71 ± 0.06 117
1b
c[RGDfV] 104.7 ± 18.9 3.2 ± 1.3 33
1c
c[RGDfK] 52.0 ± 23.8 1.4 ± 0.2 37
2 345.0 ± 1.0 3.2 ± 2.7 108
3 95.6 ± 24.6 4.5 ± 1.1 21
4 95.3 ± 4.9 7.6 ± 4.3 13
5 173.5 ± 52.5 12.6 ± 5.0 14
6 76.6 ± 4.2 2.1 ± 0.6 37
7 2.3 ± 0.8 0.2 ± 0.09 12
8
c[DKP-3-RAD] 4095 ± 1425 1500 ± 540 3
1 IC50 values were calculated as the concentration of compound required for 50% inhibition of biotinylated
fibronectin binding as estimated by GraphPad Prism software; all values are the arithmetic mean ± SD of triplicate
determinations. 2 Calculated as the concentration of compound required for 50% inhibition of biotinylated
vitronectin binding [24].
All of the cyclic DKP-RGD ligands 2–7 showed binding affinities for integrin αVβ6 lower than
those for αVβ3, displaying a selectivity ratio (IC50 αVβ6/IC50 αVβ3) ranging from about 10 (4, 5, 7) to
nearly 100 (2) (Table 1). The trend is confirmed by the reference cyclopeptides, exhibiting IC50 values for
αVβ6 about 35 (1b, 1c)–100 (1a) times higher than those for αVβ3. Among the RGD peptidomimetics,
compound 7 proved to be the best αVβ6 ligand, inhibiting the binding of biotinylated fibronectin to
αVβ6 at a low nanomolar IC50 value. Interestingly, this ligand was also the most potent αVβ3 ligand of
the series, displaying a subnanomolar IC50 value.
As a negative control in the determination of binding activities, a cyclic peptidomimetic containing
the Arg-Ala-Asp (RAD) sequence was prepared and tested (compound 8, c[DKP-3-RAD], see
Supplementary Materials, Scheme S1 and Figures S1–S6), displaying micromolar IC50 values with both
αVβ3 and αVβ6 integrins (Table 1).
2.2. Docking Model of αVβ6 Integrin and X-ray Structure Analysis
The computational model for the interaction of RGD ligands with the αVβ6 integrin was
developed by means of docking calculations using Glide V5.7 [35] (see Section 4 for a detailed
description), starting from the X-ray structure of the extracellular segment of integrin αVβ6 in complex
with the RGD-containing undecapeptide of the TGF-β3 prodomain (PDB code: 4UM9) [32].
In the crystal structure, the headpiece of αVβ6 adopts a closed conformation [32,36] similar to
that adopted by αVβ3 in the X-ray complex with Cilengitide [37]. In both of the crystal complexes
the RGD sequence shows an extended conformation characterized by a Cβ(Arg)-Cβ(Asp) distance
of 8.9 (αVβ3)–9.4 (αVβ6) Å, and a separation between the charged Arg and Asp side chains of
13.7 (αVβ3)–14.2 Å (αVβ6) (measured between the carbon atoms of the guanidinium and carboxylate
groups). As observed in other X-ray structures of integrins in complex with RGD ligands [37–40],
the RGD sequence binds at the interface of the α and β subunits with the carboxylic and guanidine
groups acting as an electrostatic clamp, respectively, on a bivalent cation of the β subunit (MIDAS, metal
ion-dependent adhesion site) and on specific acid residues of the α subunit. The oxygen atom of RGD
aspartate side chain not engaged by MIDAS Mg2+ ion forms hydrogen bonds with backbone NH groups
of β6-Asn218 and β6-Ala126. The arginine of RGD makes a bidentate side-on interaction through the
guanidinium group to the side chain of Asp218 in the αV subunit, as in binding to αVβ3, but does
not interact with αV-Asp150 side chain as for Cilengitide in αVβ3. Other stabilizing hydrogen bond
interactions occur between the backbone Gly carbonyl and Asp-NH ligand moieties and β6-Thr221
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side chain and β6-Ile219 carbonyl group, respectively. It is worth noting that the salt bridge between
αV-Asp219 and β3-Lys253 at the RGD binding site interface cannot be formed in αVβ6 due to β6-Asp256
mutation, making the αV-Asp219 residue more accessible to the interaction with the ligands.
Large differences in the ligand-binding region between αVβ6 and αVβ3 are also represented by
point mutations in the β2-β3 loop and in two neighboring interacting loops [32]. The three residues
forming pi-cation interactions in β3, Tyr166, Arg214, and Arg216, are replaced in β6 by Lys170, Ala217,
and Ile219. Furthermore, β3-Tyr122 residue, which is engaged into a pi-interaction with the Phe residue
of Cilengitide, is mutated into β6-Ala126. In addition to RGD interactions, the immediately following
LGRLK sequence of the TGF-β3 peptide forms an amphipatic α-helix that extensively interfaces with
the β6 subunit exploiting a hydrophobic pocket close to the RGD binding site. Most of the contacts are
formed with Ala126, Ser127, Cys180, Ile183, Tyr185, Ala217 side chains, and Pro179 backbone atoms.
In all of the docking calculations, the X-ray binding mode of the RGD motif with the αVβ6 integrin
was taken as a reference model for the analysis of the docking results in terms of ligand–protein
interactions. For instance, ligands 1a and 1c are able to reproduce the experimentally determined
binding mode of the RGD sequence (Figure 2), even if some hydrogen bond interactions are not
optimal in all the calculated docking poses. More importantly, 1a and 1c cannot significantly improve
the interaction with the αVβ6 binding site as gained by their D-Phe residue in the αVβ3 pocket (due to
β3-Tyr122 mutation into β6-Ala126) or by the TGF-β3 α-helix in the β6-specific hydrophobic pocket.
These considerations might explain the reduced binding affinities of these cyclic peptides for integrin
αVβ6 when compared to αVβ3. In particular, the docking poses of ligand 1a (Cilengitide) show the
D-Phe aromatic group in contact with β6-Ile183 and β6-Ala126, fitting only partially the α-helix region
and the corresponding hydrophobic pocket (Figure 2a). Conversely, the docking poses of ligand 1c
display electrostatic interactions between the ligand Lys side chain and the integrin αV-Asp150 and
αV-Asp148 residues, forcing the ligand D-Phe aromatic moiety in proximity of β6-Lys170, β6-Ser182,
and β6-Asn218 residues, far away from the α-helix binding site (Figure 2b).
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structure of the TGF-β3 undecapeptide (grey, α-helix represented as a ribbon) into integrin αVβ6 (from 
4UM9.pdb). Only selected integrin residues involved in interactions with the ligand are shown and 
labeled in blue for αV and red for β6. Non-polar hydrogens are hidden for clarity, while intermolecular 
hydrogen bonds are shown as black dashed lines. 
2.3. Docking of Cyclic DKP-RGD Peptidomimetics into αVβ6 Integrin 
Docking studies were performed starting from the macrocycle conformations of the cyclic DKP-
RGD peptidomimetics that have been previously reported [24] and are shown in Appendix A (Figure 
A1) and in the Supplementary Materials (Figures S7–S9). When compared to the X-ray RGD bound 
conformation, both type I (characterized by a distorted β-turn at Gly-Asp) and type III (characterized 
Figure 2. Docking best poses of (a) ligand 1a (green) and (b) ligand 1c (green) overlaid to the
X-ray structure of the TGF-β3 undecapeptide (grey, α-helix represented as a ribbon) into integrin
αVβ6 (from 4UM9.pdb). Only selected i tegrin residues involv d in interactions with the ligand are
shown and labeled in blue for αV nd red for β6 Non-polar hydrogens are hidden for clarity, while
intermolecular hydrogen bonds are shown as black dashed lines.
2.3. Docking f Cyclic DKP-RGD Peptidomimetics into αVβ6 Integrin
Docking studies were performed starting from the macrocycle conformations of the cyclic
DKP-RGD peptidomimetics that have been previously reported [24] a are shown in Appendix A
(Figure A1) and in the Supplementary Materials (Figures S7–S9). When compared to the X-ray
RGD bound conformation, both type I (characterized by a distorted β-turn at Gly-Asp) and type
III (characterized by a pseudo-β-turn at DKP-Arg) geometries preferentially adopted by these
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ligands, display a similar extended arrangement of the RGD sequence satisfying the pharmocophoric
requirements for the binding to integrin αVβ6. Accordingly, docking results show that the top-ranked
binding modes of all of the ligands maintain the key interactions observed for the RGD motif into
the X-ray complex. The Asp and Arg side chains fit into the corresponding charged regions of the
receptor, coordinating the MIDAS ion and forming the bidentate side-on salt bridge with αV-Asp218,
respectively. The hydrogen bonds between the oxygen atom of Asp side chain and backbone NH
groups of β6-Asn218 and β6-Ala126 are also present, as well as further stabilizing H-bonds involving
ligand Gly and Asp backbone moieties and β6-Ile219 and β6-Thr221 residues, even if they are not
optimal in all the calculated docking poses.
Since DKP-RGD compounds are highly preorganized for binding to αVβ6, the modulation of
their experimental affinity can be explained by considering the different orientation of the aromatic
rings of the DKP scaffold within the binding site. Indeed, docking results showed that, depending on
DKP scaffold (i.e., on endocyclic nitrogen N-1/N-4 substitution and carbon C-3/C-6 stereochemistry)
and macrocycle conformation, the aromatic moieties differently fit into the integrin pocket.
Docking calculations starting from type III geometry of ligand 2 place the N-4 benzyl group of
the scaffold between α and β subunits interacting with the aromatic side chain of αV-Tyr178 and with
β6-Ser182. This benzyl position could prevent optimal RGD interactions and perturb the whole ligand
binding, thus explaining its high-nanomolar experimental binding affinity (IC50 = 345.0 ± 1.0 nM).
A different binding mode of the aromatic moiety is observed in the docking poses of ligand 4 that
displays an improved binding ability (IC50 = 95.3 ± 4.9 nM). The N-1 benzyl substitution and the
type I macrocycle geometry generate docking poses with similar docking scores and RGD interactions
with respect to ligand 2, but with a different orientation of the benzyl group that interacts with
β6-Ile183, a ‘hot spot’ residue of the TGF-β3 α-helix pocket. By placing the aromatic ring in the
α-helix region, ligand 4 seems to be more effective in displacing the natural ligand in the competitive
binding assay. In line with these considerations, in the docking poses of the di-benzylated compound
5 (IC50 = 173.5 ± 52.5 nM), the aromatic moieties partially fit both of the benzyl binding regions
identified by ligands 2 and 4. When compared to the mono-benzylated compounds, the addition of
a second aromatic group improves the experimental binding affinity only with respect to ligand 2,
while it has a perturbing effect with respect to ligand 4. In fact, the docking poses of ligand 5, adopting
the type III geometry, show one benzyl group placed between αV-Tyr178 and β6-Ser182 (as in ligand 2),
and the second one exposed to the solvent or in contact with β6-Ile183 (as in ligand 4). The absence of
a stable interaction of the benzyl moieties with key residues of the hydrophobic β6 pocket is probably
responsible for the intermediate affinity of 5 for the receptor. The superimposition of the best poses of
the three ligands (featuring the same 3R, 6S scaffold configuration) is shown in Figure 3a.
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(a) (b)
Figure 3. Docking best poses of (a) ligands 2 (red), 4 (green) and 5 (blue) and (b) ligands 3 (red), 6 
(green) and 7 (blue) into integrin αVβ6 (αV surface in grey, β6 surface in yellow). The X-ray structure 
of the TGF-β3 α-helix portion is shown as a grey ribbon. Ligand aromatic rings are represented as 
space-filling spheres. 
Figure 3. Docking best poses of (a) ligands 2 (red), 4 (green) and 5 (blue) and (b) ligands 3 (red),
6 (green) and 7 (blue) into integrin αVβ6 (αV surface in grey, β6 surface in yellow). The X-ray structure
of the TGF-β3 α-helix portion is shown as a grey ribbon. Ligand aromatic rings are represented as
space-filling spheres.
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In the docking poses of ligand 3, featuring the type III macrocycle geometry and the N-4 benzyl
substitution, the aromatic moiety is shifted towards β6-Glu316, β6-Gln317, and β6-Asp254 residues
close to the ADMIDAS (adjacent to MIDAS) ion, forming a large number of favorable contacts with the
protein. When compared to ligand 4, the benzyl group fits a different protein region that stabilizes the
binding of the RGD motif, as suggested by the experimental receptor affinity (IC50 = 95.6 ± 24.6 nM).
For ligand 6, the switch to type I macrocycle conformation and to N-1 benzyl substitution produces
ligand poses with the aromatic ring in contact withβ6-Ile183 of theα-helix pocket. Such a binding mode
corresponds to the docking pose observed for ligand 4 and nicely agrees with the experimental IC50
value of 76.6 ± 4.2 nM, suggesting that the position of the aromatic ring close to α-helix hydrophobic
region has a stabilizing effect on ligand binding. The docking poses of ligand 7, the most active
compound of the library exhibiting a low nanomolar IC50 value, show some similarities with both
ligands 3 and 6. The presence of two aromatic rings improves the experimental integrin affinity as
compared to the mono-benzylated analogs, because both benzyl groups productively contribute to
ligand stabilization. In particular, ligand 7, adopting the type I geometry, docks one benzyl group in the
protein region explored by ligand 3, forming contacts with β6-Glu316 and β6-Gln317 residues, and the
other one in theα-helix hydrophobic pocket, nicely overlapping theα-helix region and forming contacts
with β6-Ile183, β6-Ala126, and β6-Ser127. Interestingly, ligand 7 displays the best docking score among
all of the investigated compounds (see the Supplementary Materials, Table S1) and the highest number
of docking poses maintaining all the crystallographic RGD interactions. The superimposition of the
best poses of the three ligands featuring the same 3S, 6R scaffold configuration is shown in Figure 3b.
Finally, docking calculations on compound 8 (c[DKP-3-RAD], used as a negative control), starting
from the type III geometry, fail in reproducing the X-ray key interactions of Asp and Arg residues.
In the best pose of the stereoisomer containing the (S)-Ala amino acid the carboxylate group coordinates
the ADMIDAS Ca2+ ion, while the guanidinium group form a pi-cation interaction with αV-Tyr178
side chain. In the best pose of the stereoisomer containing the (R)-Ala residue, the coordination of
the Asp side chain to MIDAS Mg2+ is kept (without hydrogen bonds to β6 residues), while the Arg
side chain interacts with αV-Asp148 and αV-Asp150. Accordingly, the docking scores of the RAD
peptidomimetics are about 1–3 kcal/mol worse than those calculated for the RGD ligands (see the
Supplementary Materials, Table S1).
3. Discussion
In view of the roles played by integrin αVβ6 in cancer growth and progression [5–9,41],
small-molecule integrin antagonists may be a valuable tool to modulate these processes. Investigating
the interaction of cyclic RGD peptidomimetics with this integrin subtype represents the first essential
step towards their exploitation as inhibitors of integrin functions and as receptor ligands for targeted
therapy and imaging of tumors. The cyclic DKP-RGD peptidomimetics 2–7 have been designed to
target the αVβ3 integrin, qualifying as excellent ligands (from low- to sub-nanomolar IC50 values in
the inhibition of biotinylated vitronectin binding to αVβ3) of this RGD-recognizing heterodimer [24].
Prompted by the similarity of the ligand RGD binding observed in the crystal structures of Cilengitide
to αVβ3 and TGF-β3 peptide to αVβ6 [32,37], we decided to investigate the interaction of the cyclic
peptidomimetics with the αVβ6 integrin by means of competitive cell-free binding assays and docking
studies. Indeed, the favored geometries of these ligands are characterized by an extended arrangement
of the RGD sequence comparable to the X-ray αVβ6-bound RGD conformation and suitable to establish
useful interactions with αVβ6 integrin.
Accordingly, docking calculations of the cyclic peptidomimetics in the αVβ6 crystal structure
predicted RGD binding modes reproducing the key interactions found in the X-ray complex of TGF-β3
peptide to αVβ6. In particular, the electrostatic clamp of ligand Arg and Asp side chains with the
corresponding charged regions in the αV and β6 receptor subunits is properly formed, in combination
with a stabilizing network of hydrogen bonds whose specific features depend on the structural
properties of each particular ligand (e.g., scaffold substitution and stereochemistry).
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However, similar to what is observed for cyclic RGD peptides, the peptidomimetics exhibited
binding affinities for the αVβ6 integrin (measured as the concentration of compound required for 50%
inhibition of biotinylated fibronectin binding to isolated αVβ6 integrin) about 10–100 times lower than
those for the related αVβ3 receptor (Table 1). Although the RGD binding mode found in αVβ6 integrin
recapitulates the RGD interaction with αVβ3, differences between integrin binding pockets can affect
the ligand recognition and binding ability. For instance, β3-Tyr122 residue, which is engaged into a
pi-interaction with the D-Phe residue of Cilengitide [37] or with a suitable aromatic moiety of the cyclic
DKP-RGD peptidomimetics 2–7 [24], is mutated into β6-Ala126, hampering an important contribution
to the complex stabilization.
More importantly, further sequence differences between the β subunits create a β6-specific
hydrophobic pocket that was shown to play a key role in the elucidation of specificity determinants
of integrin β subunits [32]. In particular, three βI-domain loops contribute to the main difference
in the ligand-binding region between αVβ6 and αVβ3 [32]. The amphipathic α-helix of the TGF-β3
undecapeptide makes extensive contacts with these three loops, fully exploiting the hydrophobic
pocket composed only of residues from the β6 subunit, and acting to stabilize the RGD interaction.
Interestingly, in contrast to the αVβ6 complex, complexes of αVβ3, αIIbβ3, and α5β1 exhibit little
interaction beyond that with the RGD motif [37–40].
As shown by docking results, the cyclic DKP-RGD peptidomimetics 2–7 can only partially
take advantage of the structural peculiarity of αVβ6 integrin, fitting the hydrophobic pocket to an
incomplete extent thanks to the structural features of specific ligands. In particular, the analysis of
the docking poses suggests that the interactions of the DKP benzyl moieties with key residues of
the hydrophobic β6 pocket as well as their overlap with the α-helix region of the TGF-β3 peptide,
correlate well with the ability of the cyclic peptidomimetics to displace the natural ligand in competitive
binding assays. Indeed, ligand 7, displaying the best fit to the TGF-β3 peptide and the most favorable
interactions with αVβ6 integrin for both the RGD and not-RGD portions in the calculated binding
modes, appears the best αVβ6 ligand of the library, inhibiting the binding of biotinylated fibronectin to
αVβ6 at a low nanomolar IC50 value (2.3 ± 0.8 nM).
Recently, a cyclic RGD peptide endowed with sub-nanomolar binding affinity toward the αVβ6
integrin and a remarkable selectivity against other integrins has been reported as a result of a strategy
based on the grafting of the epitope from the αVβ6 binding helix onto a cyclic β-sheet structure [42].
Although, in contrast to linear peptides [43], the DLXXL-motif was not essential for the αVβ6 activity of
the cyclic peptides, three RGD-flanking hydrophobic residues were shown to significantly contribute
to the interaction, fitting the wide hydrophobic pocket and projecting their side chains in the same
direction as the key residues of the TGF-β3 helical motif [42].
In conclusion, experimental and computational tools for the evaluation of αVβ6 integrin ligands
have been set up and then applied to investigate the interaction of cyclic RGD peptidomimetics with
αVβ6 integrin. In particular, a docking protocol was defined and then exploited to predict the binding
mode of the cyclopeptides to the αVβ6 integrin, generating poses that fairly reflect the results of the
competitive binding assays to the isolated receptor. Insights from the features of the binding pocket
combined with the analysis of the docking poses provided a rationale for ligand recognition and
enabled to outline the molecular bases of ligand binding affinities. This understanding might in turn be
exploited to develop αVβ6-selective ligands and improved targeting agents for biomedical applications.
4. Materials and Methods
4.1. Integrin Ligands
The cyclic peptidic and peptidomimetic RGD ligands used in this work were purchased or
synthesized according to published procedures [17,24]. The synthesis and the characterization of the
new cyclic peptidomimetic c[DKP-3-RAD] 8 are reported in the Supplementary Materials (Scheme S1,
Figures S1–S6).
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4.2. Solid-Phase Receptor Binding Assay
Recombinant human integrin αVβ6 receptor (R&D Systems, Minneapolis, MN, USA) was diluted
to 1.0 µg/mL in coating buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MnCl2,
2 mM CaCl2, and 1 mM MgCl2. An aliquot of diluted receptor (100 µL/well) was added to 96-well
microtiter plates (Nunc MaxiSorp, Thermo Fisher Scientific, Roskilde, Denmark) and incubated
overnight at 4 ◦C. The plates were incubated with blocking solution (coating buffer plus 1% bovine
serum albumin) for additional 2 h at room temperature to block nonspecific binding. After washing
twice with blocking solution, plates were incubated shaking in the dark for 3 h at room temperature,
with various concentrations (10−4–10−11 M) of test compounds in the presence of 1 µg/mL biotinylated
fibronectin (Molecular Innovations, Novi, MI, USA). Biotinylation was performed using an EZ-Link
Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL, USA). After washing three times, the plates were
incubated shaking for 1 h, at room temperature, with streptavidin-biotinylated peroxidase complex
(Amersham Biosciences, Uppsala, Sweden). After washing 3 times with blocking solution, plates were
incubated with 100 µL/well of Substrate Reagent Solution (R&D Systems) for 30 min shaking in the
dark, before stopping the reaction with the addition of 50 µL/well 2N H2SO4. Absorbance at 415 nm
was read in a SynergyTM HT Multi-Detection Microplate Reader (BioTek Instruments, Inc., Winooski,
VT, USA). Each data point represents the average of triplicate wells; data analysis was carried out by
nonlinear regression analysis with GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA,
USA). Each experiment was repeated in triplicate.
4.3. Computational Studies
Protein setup. The crystal structure of the extracellular domain of the integrin αVβ6 in complex
with the HGRGDLGRLKK undecapeptide of the TGF-β3 prodomain (PDB code: 4UM9) [32] was
used for docking studies. Docking was performed only on the globular head of the integrin,
because the headgroup of integrin has been identified in the X-ray structure as the ligand-binding
region. The protein was truncated to residue sequences 1–439 for chain α (chain C of crystal
asymmetric unit) and 114–355 for chain β (chain D of crystal asymmetric unit). According to the X-ray
structure, the bivalent cation at MIDAS has been modeled as Mg2+ ion, whereas all of the other metal
cations were modeled as Ca2+ ions. All waters molecules were deleted except for the three water
molecules coordinating the MIDAS cation and the single water molecule found around ADMIDAS
ion. The structure was then prepared by using the Protein Preparation Wizard of the graphical user
interface Maestro and the OPLSAA force field [44]. Hydrogen bonds were optimized according to the
exhaustive sampling option and the entire complex was optimized by using a restrained minimization
with convergence on heavy atoms to a RMSD (root-mean-square deviation) of 0.30 Å.
Ligand docking calculations. The automated docking calculations were performed by using Glide
V5.7 in the standard precision (SP) mode [35]. The grids were generated for the RGD-integrin αVβ6
complex structure prepared as described in the protein setup section. The center of the grid-enclosing
box was defined by the center of the bound ligand. For the grid generation step, the size of the
inner cubic box for placing the ligand center was set to 12 Å, and a value of 26 Å was used for the
outer cubic box. The outer box dimensions fit the entire active site. No further modifications were
applied to the default settings. For the docking calculations, the GlideScore function was used to select
20 poses for each ligand after a post-minimization step. The flexible docking option was selected
and the SP modality was used with amide bonds set to trans configurations. No Epik state penalty
was added to the docking score and all of the ligands were considered in their zwitterionic form
(and protonated Lys residue for 1c). To validate the docking protocol, a known αVβ6 ligand was
selected, i.e., the cyclic pentapeptide c[RGDfK] 1c, showing an IC50 value to the isolated receptor
of 52.0 ± 23.8 nM (see Table 1). In fact, due to the high conformational flexibility, the X-ray ligand
(the undecapeptide of the TGF-β3 prodomain) is not suitable for standard docking calculations.
For compound c[RGDfK] 1c, Glide succeeded in reproducing the experimentally determined binding
mode of the RGD motif, as it corresponds to the best-scored pose (see Figure 2b).
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Ligand conformations. The conformations of the ligands used in docking studies are described in
the Appendix A. To avoid incomplete sampling of macrocycle conformations during docking analyses,
the assessment of the preferred conformations of the cyclic systems has been performed as a separate
step before docking [45].
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/9/10/128/s1.
Scheme S1: Synthesis of compound 8, Figures S1–S6: HPLC traces and NMR spectra of compound 8,
Figures S7–S9: Preferred conformations identified for the cyclic [DKP-RGD] peptidomimetics (2D and 3D
representations), Table S1: Glide docking score values of the best poses.
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Appendix A
Docking studies were performed starting from the preferred macrocycle conformations of
the cyclic DKP-RGD peptidomimetics previously determined [24,46]. Four different geometries
(denoted as type I–IV) were identified in the free state conformational analysis of the cyclic RGD
ligands containing the DKP scaffolds, by means of computational and spectroscopic NMR studies,
as summarized in the Supplementary Materials. Depending on the configuration and substitution of
the DKP scaffold, the cyclic DKP-RGD ligands showed different intramolecular H-bonding patterns as
characterized by specific β- and γ-turns and diverse arrangements of the RGD sequence. In Figure A1,
the type I and III patterns are shown as they correspond to the preferred macrocycle conformations
adopted by the compounds under investigation. Docking calculations of ligand 6 were also run from
type IV geometry, obtaining results worse than those provided by type I.
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Figure A1. (a) 2D representation of type I geometry; (b) 2D representation of type III geometry.
As the NMR-based solution structures of 1a (Cilengitide) exhibit conformations closely resembling
the crystal structure bound to the head group of integrin αVβ3, docking calculations were performed
from the X-ray αVβ3-bound geometry [47]. Interestingly, the type I conformation of the cyclic
DKP-RGD peptidomimetics is very similar to this geometry.
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Metropolis Monte Carlo/Stochastic Dynamics (MC/SD) simulations [48], using the implicit water
GB/SA solvation model [49], were performed on ligand 1c within the framework of MacroModel
V9.9 [50]. MC/SD simulations were performed at 300 K using the all-atoms AMBER* force field and
a time step of 1 fs for 20 ns of simulation time. Side-chain dihedral angles were defined as internal
coordinate degrees of freedom in the Monte Carlo part of the algorithm. A total of 5000 conformations
were stored for analysis. To assess the convergence of the calculations, three independent MC/SD
simulations were run starting from different macrocycle conformations. The analysis of the
sampled structures showed that during all of the simulations compound 1c preferentially adopts an
extended arrangement of the RGD sequence, characterized by a β-turn centered on Gly-Asp residues,
comparable to the X-ray αVβ3–bound geometry of Cilengitide. Macrocycle conformations featuring
a β-turn at D-Phe-Lys or a β-turn at Lys-Arg were also sampled during the MC/SD simulations.
Three representative macrocycle conformations were then used for docking calculations and the best
results were obtained starting from the preferred Gly-Asp β-turn conformation.
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